Vanda Pharmaceuticals Inc. (VNDA) shares jumped 29.13%, trading at $9.08, up $2.05, after the company announced that the U.S. Food and Drug Administration approved NEREUS (tradipitant) for the prevention of vomiting induced by motion sickness, the first such approval in over 40 years.
The FDA's decision was based on positive results from pivotal clinical trials demonstrating significant reductions in vomiting compared with placebo, positioning NEREUS as a novel treatment for a condition affecting millions of adults.
On the day of the announcement, VNDA opened near $7.50, climbed to an intraday high above $9.20, and saw a low near $7.45, compared with a previous close below $7.10. The stock trades on the Nasdaq.
Trading volume was indicating strong investor interest following the regulatory milestone. Vanda's 52-week range reflects typical biotech volatility influenced by regulatory and clinical developments.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.